In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice

CRISPR/Cas9 screening approaches are powerful tool for identifying in vivo cancer dependencies. Hematopoietic malignancies are genetically complex disorders in which the sequential acquisition of somatic mutations generates clonal diversity. Over time, additional cooperating mutations may drive dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bin E., Li, Grace Y., Cai, Wenqing, Zhu, Qian, Seruggia, Davide, Fujiwara, Yuko, Vakoc, Christopher R., Orkin, Stuart H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506108/
https://www.ncbi.nlm.nih.gov/pubmed/37428871
http://dx.doi.org/10.1182/bloodadvances.2022009455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506108/
https://www.ncbi.nlm.nih.gov/pubmed/37428871
http://dx.doi.org/10.1182/bloodadvances.2022009455

Ejemplares similares